Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05479669
Other study ID # VIP-HF 2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 29, 2022
Est. completion date January 1, 2031

Study information

Verified date May 2024
Source University Medical Center Groningen
Contact Michiel Rienstra, MD PhD
Phone 0031503612878
Email m.rienstra@umcg.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Heart failure (HF) with a left ventricular ejection fraction (LVEF) >0.40 is a large medical problem, for which no drug or device has a recommendation in current HF guidelines. The prevalence of mortality and HF hospitalizations in HF with LVEF >0.40 is high, but the identification of predictors for increased risk of mortality and HF hospitalizations in this patient category remains difficult. The hypothesis of this study is that the risk of all-cause mortality and HF hospitalizations can be measured by clinical factors, imaging parameters and circulating biomarkers, and that these factors can be used in a risk profile


Description:

Objective: To assess the risk profile associated with the combined endpoint of all-cause mortality and HF hospitalizations in HF patients with LVEF >0.40. Study design: Single-center, prospective, study. Study population: We aim 200 patients with symptomatic heart failure (NYHA class II-III), and a recent HF hospitalization, emergency room visit or symptom relief with diuretics who have a left ventricular ejection fraction >0.40, echocardiographic evidence of left atrial enlargement or left ventricular hypertrophy, and elevated concentrations of BNP or NT-proBNP. Study procedures: All patients will undergo echocardiography, cardiac magnetic resonance (CMR) imaging, Holter recording and blood sampling at inclusion. The 99mTc-HDP scan is optional.There is no control group. Total follow up: Up to five years. Main study endpoint: incidence of the combined endpoint of all-cause mortality and HF hospitalizations.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date January 1, 2031
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Clinical criteria: 1. Age >18 years 2. Written informed consent 3. HF with moderate to severe symptoms NYHA II or III 4. Hospitalization or emergency room visit for HF or symptom relief with diuretics 5. Sinus rhythm or AF Echocardiographic criteria: 1. LVEF >0.40 2. Left atrial size (volume =29 mL/m2 or LA parasternal diameter =45), or left ventricular hypertrophy (septal thickness or posterior wall thickness =11 mm) or LV diastolic dysfunction (E/e' =13 or mean e' septal and lateral wall <9 cm/s). Biomarker criteria: 1. BNP >31ng/L or NT-pro-BNP>125ng/L if sinus rhythm 2. BNP >75ng/L or NT-pro-BNP>300ng/L if atrial fibrillation Exclusion Criteria: 1. Patients unwilling or unable to sign informed consent 2. Patients with a pacemaker or ICD 3. Indication for ICD therapy according to the ESC guidelines 4. Life expectancy of less than one year 5. Significant coronary artery disease or myocardial infarction < 3 months 6. Complex congenital heart disease 7. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Echocardiography
Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
24 hour Holter monitoring
24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
Cardiac Magnetic Resonance Imaging
Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
99mTc-HDP scan
Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
ECG
A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Combined endpoint of all-cause mortality and hospitalization for heart failure The incidence of the combined endpoint of all-cause mortality and first heart failure hospitalization 5 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04573166 - Personalized Atrial Septostomy for Heart Failure N/A
Recruiting NCT02425371 - Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) Phase 3
Terminated NCT03312387 - Muscle, Essential Amino Acids, and eXercise in Heart Failure N/A
Completed NCT05475028 - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT02334891 - Kyoto Congestive Heart Failure Study
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT05139472 - Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction Phase 3
Recruiting NCT04682704 - The Effect of Different Low-Level Tragus Stimulation Parameters On Autonomic Nervous System Function N/A
Completed NCT03924479 - Respiratory Muscle Function in Heart Failure N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Completed NCT02589977 - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Phase 4
Completed NCT02946476 - Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients N/A
Recruiting NCT04179643 - NAN-101 in Patients With Class III Heart Failure Phase 1
Recruiting NCT05425459 - RESPONDER-HF Trial N/A
Completed NCT04940312 - MyoMobile Study: App-based Activity Coaching in Patients With Heart Failure and Preserved Ejection Fraction
Recruiting NCT04602338 - Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
Completed NCT03240237 - CCM in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05887271 - A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction Phase 2/Phase 3
Completed NCT02408003 - Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support. N/A